Primary hyperoxaluria (PH) is the most severe of the stone diseases, causing recurring stones from childhood on and end stage renal failure. Progress toward effective treatments has been slow. Our experience with the International Primary Hyperoxaluria Registry (IPHR) has resulted in better understanding of disease expression, early recognition of factors associated with loss of renal function, has suggested treatment strategies likely to be successful, and has facilitated sufficient numbers of patients to test new treatments in clinical trials of betaine and Oxalobacter, to date. The goals of the current project are to: (1) Expand our current PH registry to determine the factors associated with nephrocalcinosis, stone formation, and renal injury (2) Generate testable hypotheses regarding mechanisms of renal injury in these diseases through registry findings, tissue resources, and pilot projects. (3) Explore new avenues of treatment. (4) Develop cohorts of well-characterized patients for future clinical studies, (5) Explore new areas of partnership with the Oxalosis and Hyperoxaluria Foundation (OHF) (6) Provide ready access to high quality resources and information for physicians and scientists and (7) Attract and train investigators to rare diseases research. We will accomplish these goals through a consortium of clinician and basic scientists expert in PH, a network of study sites, and close collaboration with the OHF to more effectively reach and educate health care providers and patients. The 4 Specific Aims are to: S.A. 1a. Expand the PH registry containing clinical data for longitudinal follow-up of patients, identifying wellcharacterized cohorts of patients available for future treatment studies. 1 b. Expand the PH tissue bank S.A. 2a. Identify genetic modifiers of disease expression, specifically early onset of ESRD 2b. Perform molecular screening of TGF p as a candidate modifier gene. S.A. 3. Evaluate hydroxyproline as a potential metabolic precursor of oxalate in PH types 1 and 2. S.A. 4a. Create web-based educational materials at the highest scientific and medical level, to allow creation of patient material by the Oxalosis and Hyperoxaluria Foundation for international dissemination. 4b. Provide high quality information and resources regarding PH for physicians, clinical and basic scientists. We will also apply our experience with the IPHR to create a similar structure and activities for other hereditary causes of nephrolithiasis and renal failure: cystinuria, APRT deficiency, and Dent disease. Synergies will allow rapid transfer of experience and advancement of patient care.

Public Health Relevance

Progress toward more effective treatment for patients with primary hyperoxaluria has been slow due the rarity of this condition. To address this problem we will further develop the International Primary Hyperoxaluria Registry and tissue bank, augment collaborations with key scientists, conduct pilot projects, and explore new areas of partnership with the OHF to engage patients and their physicians in order to better characterize disease expression, generate innovative hypotheses, and test new treatments.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Nazzal, Lama; Puri, Sonika; Goldfarb, David S (2016) Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrol Dial Transplant 31:375-82
Kovacevic, Larisa; Lu, Hong; Caruso, Joseph A et al. (2016) Renal Tubular Dysfunction in Pediatric Urolithiasis: Proteomic Evidence. Urology 92:100-5
Runolfsdottir, Hrafnhildur Linnet; Palsson, Runolfur; Agustsdottir, Inger M et al. (2016) Kidney Disease in Adenine Phosphoribosyltransferase Deficiency. Am J Kidney Dis 67:431-8
Brooks, Ellen R; Hoppe, Bernd; Milliner, Dawn S et al. (2016) Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. Am J Nephrol 43:293-303
Amin, Rasheda; Eid, Loai; Edvardsson, Vidar O et al. (2016) An unusual cause of pink diapers in an infant: Questions and Answers. Pediatr Nephrol 31:575, 577-80
Lieske, John C; Turner, Stephen T; Edeh, Samuel N et al. (2016) Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J Nephrol 29:45-51
Whittamore, Jonathan M; Hatch, Marguerite (2016) The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man. Urolithiasis :
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Tang, Xiaojing; Brown, Matthew R; Cogal, Andrea G et al. (2016) Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients. Physiol Rep 4:
Zhao, Fang; Bergstralh, Eric J; Mehta, Ramila A et al. (2016) Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol 11:119-26

Showing the most recent 10 out of 62 publications